Critical Comparison: Ascendis Pharma A/S (NASDAQ:ASND) versus Praxis Precision Medicines (NASDAQ:PRAX)

Ascendis Pharma A/S (NASDAQ:ASND) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Risk and Volatility

Ascendis Pharma A/S has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.85, meaning that its stock price is 185% more volatile than the S&P 500.

Profitability

This table compares Ascendis Pharma A/S and Praxis Precision Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Ascendis Pharma A/S and Praxis Precision Medicines, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0	2	19	0	2.90
Praxis Precision Medicines	2	0	17	3	2.95

Ascendis Pharma A/S presently has a consensus target price of $305.95, indicating a potential upside of 18.75%. Praxis Precision Medicines has a consensus target price of $630.42, indicating a potential upside of 102.62%. Given Praxis Precision Medicines’ stronger consensus rating and higher possible upside, analysts plainly believe Praxis Precision Medicines is more favorable than Ascendis Pharma A/S.

Valuation & Earnings

This table compares Ascendis Pharma A/S and Praxis Precision Medicines”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57 million	19.73	-$258.00 million	$12.89	19.99
Praxis Precision Medicines	N/A	N/A	-$303.27 million	($12.93)	-24.06

Ascendis Pharma A/S has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

67.8% of Praxis Precision Medicines shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Ascendis Pharma A/S beats Praxis Precision Medicines on 9 of the 14 factors compared between the two stocks.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.